Psoriasis
What the FAA's documents say about psoriasis, in plain words, with the FAA's own words one press away.
- The psoriasis table and worksheet both point psoriatic arthritis to the arthritis worksheet.
Short version
The FAA's table sorts it into three rows.
| Situation | What the examiner does | Pathway |
|---|---|---|
| Row AMild to moderate disease confined to the skin, and treated with topical medication only. | Examiner issues | Examiner can issue |
| Row BMild to moderate disease, and treated with oral or injectable medication. The row says that if psoriatic arthritis is present, see the CACI worksheet for arthritis. | Worksheet | CACI |
| Row CAll others, including erythrodermic psoriasis, pustular psoriasis and severe psoriasis. | Defers to the FAA | Special Issuance |
Show the FAA's words: the FAA's table for Psoriasis
- Row A · Examiner can issue
Mild to moderate disease confined to the skin, and treated with topical medication only. If the examiner can determine the condition is under control, current medications are acceptable, and there are no symptoms that would interfere with flight or safety related duties, the table says ISSUE, and has the examiner annotate this information in Block 60.
A. Mild to moderate disease confined to the skin AND Treated with topical medication only … If the AME can determine the condition is under control, current medications are acceptable, and no symptoms that would interfere with flight or safety related duties: ISSUE … Annotate this information in Block 60.
- Row B · CACI
Mild to moderate disease, and treated with oral or injectable medication. The row says that if psoriatic arthritis is present, see the CACI worksheet for arthritis. The table sends the examiner to the CACI worksheet for psoriasis, and says this requires a current, detailed clinical progress note from the treating physician. If the pilot meets all the worksheet's criteria and is otherwise qualified, the table says ISSUE. The examiner annotates the elements or findings in Block 60, annotates the correct CACI statement in Block 60, and keeps the required supporting information on file.
B. Mild to moderate disease AND Treated with oral or injectable medication If psoriatic arthritis present, see CACI – Arthritis Worksheet … See the CACI - Psoriasis Worksheet. This requires a current, detailed Clinical Progress Note from the treating physician. If the pilot meets all CACI worksheet criteria and is otherwise qualified: ISSUE … Annotate (elements or findings) in Block 60. Annotate the correct CACI statement in Block 60 and keep the required supporting information on file.
- Row C · Special Issuance
All others, including erythrodermic psoriasis, pustular psoriasis and severe psoriasis. The table lists what to submit for FAA review. The examiner defers, submits the information to the FAA for a possible Special Issuance, and annotates the elements or findings in Block 60.
C. All others including: • Erythrodermic psoriasis • Pustular psoriasis • Severe psoriasis … Submit the following for FAA review: … DEFER Submit the information to the FAA for a possible Special Issuance Annotate (elements or findings) in Block 60.
The FAA pathways for psoriasis
- How this pathway works: Examiner can issueNo special pathwayRow A
- How this pathway works: CACIConditions AMEs Can IssueRow B
- How this pathway works: Special IssuanceAuthorization for Special Issuance of a Medical CertificateRow C
- How this pathway works: AASIAME Assisted Special IssuanceAfter the FAA decides
Which exam
Your step-by-step plan
Step 1: The progress note from the treating doctor or specialist
The note the examiner reviews, and what the worksheet looks for in it.Within 90 days before the examA current, detailed progress note from a clinic visit with your treating physician or specialist, no more than 90 days before the exam. Your AME reviews it.
What the worksheet looks for
- Stable, with no systemic symptoms
- No limitation to strength, function, or range of motion which would interfere with flight duties
- Severity mild to moderate
The subtype
- Most subtypes, including guttate psoriasis and plaque psoriasis
- Not: Pustular psoriasis
- Not: Erythrodermic psoriasis
Other conditions
If co-morbid conditions are present, the worksheet points to their page, and psoriatic arthritis to the arthritis page.
Show the FAA's words: The progress note from the treating doctor or specialist
the AME must review a current, detailed Clinical Progress Note generated from a clinic visit with the treating physician or specialist no more than 90 days prior to the AME exam.
FAA source: CACI – Psoriasis Worksheet. FAA date 27 August 2025; checked by Crosscheck 14 October 2026.
A current, detailed Clinical Progress Note from the treating physician [ ] Condition is stable with NO systemic symptoms and NO limitation to strength, function, or range of motion which would interfere with flight duties.
FAA source: CACI – Psoriasis Worksheet. FAA date 27 August 2025; checked by Crosscheck 14 October 2026.
[ ] Severity is mild to moderate.
FAA source: CACI – Psoriasis Worksheet. FAA date 27 August 2025; checked by Crosscheck 14 October 2026.
Causes [ ] Most subtypes to include: guttate psoriasis, plaque psoriasis. Not acceptable: pustular psoriasis, erythrodermic psoriasis.
FAA source: CACI – Psoriasis Worksheet. FAA date 27 August 2025; checked by Crosscheck 14 October 2026.
NOTE: If co-morbid conditions are present, see corresponding page. If psoriatic arthritis, see arthritis page.
FAA source: CACI – Psoriasis Worksheet. FAA date 27 August 2025; checked by Crosscheck 14 October 2026.
Step 2: Medications
The medications the worksheet lists, and the observation time after each dose.Medications from the worksheet's list.
Acceptable
- Topical medication(s)
- Azathioprine (Imuran)
- Methotrexate (Trexall)
- Any single medication from the list below, after a 2-week ground trial
Post-dose observation time
- None
- Apremilast (Otezla)
- 4 hours
- Adalimumab (Humira or FDA approved biosimilar), certolizumab (Cimzia), etanercept (Enbrel), guselkumab (Tremfya), ixekizumab (Taltz), risankizumab (Skyrizi), secukinumab (Cosentyx), ustekinumab (Stelara)
- 24 hours
- Infliximab (Inflect; Remicade; Renflexis)
Show the FAA's words: Medications
Medications for condition Combinations acceptable for CACI Include: • Topical medication + • Methotrexate + • Any single agent listed
[ ] Topical medication(s) and/or [ ] azathioprine (Imuran) and/or [ ] methotrexate (Trexall) and/or [ ] Any single medication listed below after a 2-week ground trial and:
FAA source: CACI – Psoriasis Worksheet. FAA date 27 August 2025; checked by Crosscheck 14 October 2026.
Any single medication listed below after a 2-week ground trial and: No post-dose observation time: apremilast (Otezla) - PD4E 4-hour post-dose observation time: adalimumab ( Humira or FDA approved biosimilar*) - TNF certolizumab (Cimzia) - TNF etanercept (Enbrel) - TNF guselkumab (Tremfya) - IL ixekizumab (Taltz) - IL risankizumab (Skyrizi) - IL secukinumab (Cosentyx) - IL ustekinumab (Stelara) - IL 24-hour post-dose observation time: infliximab (Inflect; Remicade; Renflexis) - TNF
*Biologics do not have generic; they have biosimilar.
FAA source: CACI – Psoriasis Worksheet. FAA date 27 August 2025; checked by Crosscheck 14 October 2026.
What the examiner checks
It depends on which row of the FAA's table describes the case.
Row AExaminer issuesExaminer can issue
If the examiner can determine the condition is under control, current medications are acceptable, and there are no symptoms that would interfere with flight or safety related duties, the table says ISSUE, and has the examiner annotate this information in Block 60.
Row BWorksheetCACI
The table sends the examiner to the CACI worksheet for psoriasis, and says this requires a current, detailed clinical progress note from the treating physician. If the pilot meets all the worksheet's criteria and is otherwise qualified, the table says ISSUE. The examiner annotates the elements or findings in Block 60, annotates the correct CACI statement in Block 60, and keeps the required supporting information on file.
Row CDefers to the FAASpecial Issuance
The table lists what to submit for FAA review. The examiner defers, submits the information to the FAA for a possible Special Issuance, and annotates the elements or findings in Block 60.
If the examiner defers
Show the FAA's words: what the examiner does on each row
- Row A · Examiner can issue
Mild to moderate disease confined to the skin, and treated with topical medication only. If the examiner can determine the condition is under control, current medications are acceptable, and there are no symptoms that would interfere with flight or safety related duties, the table says ISSUE, and has the examiner annotate this information in Block 60.
A. Mild to moderate disease confined to the skin AND Treated with topical medication only … If the AME can determine the condition is under control, current medications are acceptable, and no symptoms that would interfere with flight or safety related duties: ISSUE … Annotate this information in Block 60.
- Row B · CACI
Mild to moderate disease, and treated with oral or injectable medication. The row says that if psoriatic arthritis is present, see the CACI worksheet for arthritis. The table sends the examiner to the CACI worksheet for psoriasis, and says this requires a current, detailed clinical progress note from the treating physician. If the pilot meets all the worksheet's criteria and is otherwise qualified, the table says ISSUE. The examiner annotates the elements or findings in Block 60, annotates the correct CACI statement in Block 60, and keeps the required supporting information on file.
B. Mild to moderate disease AND Treated with oral or injectable medication If psoriatic arthritis present, see CACI – Arthritis Worksheet … See the CACI - Psoriasis Worksheet. This requires a current, detailed Clinical Progress Note from the treating physician. If the pilot meets all CACI worksheet criteria and is otherwise qualified: ISSUE … Annotate (elements or findings) in Block 60. Annotate the correct CACI statement in Block 60 and keep the required supporting information on file.
- Row C · Special Issuance
All others, including erythrodermic psoriasis, pustular psoriasis and severe psoriasis. The table lists what to submit for FAA review. The examiner defers, submits the information to the FAA for a possible Special Issuance, and annotates the elements or findings in Block 60.
C. All others including: • Erythrodermic psoriasis • Pustular psoriasis • Severe psoriasis … Submit the following for FAA review: … DEFER Submit the information to the FAA for a possible Special Issuance Annotate (elements or findings) in Block 60.
The CACI worksheet's criteria
Progress note
What the worksheet looks for
- Stable, with no systemic symptoms
- No limitation to strength, function, or range of motion which would interfere with flight duties
- Severity mild to moderate
The subtype
- Most subtypes, including guttate psoriasis and plaque psoriasis
- Not: Pustular psoriasis
- Not: Erythrodermic psoriasis
Other conditions
If co-morbid conditions are present, the worksheet points to their page, and psoriatic arthritis to the arthritis page.
Your psoriasis medications
Acceptable
- Topical medication(s)
- Azathioprine (Imuran)
- Methotrexate (Trexall)
- Any single medication from the list below, after a 2-week ground trial
Post-dose observation time
- None
- Apremilast (Otezla)
- 4 hours
- Adalimumab (Humira or FDA approved biosimilar), certolizumab (Cimzia), etanercept (Enbrel), guselkumab (Tremfya), ixekizumab (Taltz), risankizumab (Skyrizi), secukinumab (Cosentyx), ustekinumab (Stelara)
- 24 hours
- Infliximab (Inflect; Remicade; Renflexis)
Show the FAA's words: the CACI worksheet's criteria for Psoriasis
- Stable, with no systemic symptoms and no limitation that would interfere with flight duties
FAA criterion, beside the current, detailed progress note from the treating physician: the condition is stable with no systemic symptoms and no limitation to strength, function, or range of motion which would interfere with flight duties.
A current, detailed Clinical Progress Note from the treating physician [ ] Condition is stable with NO systemic symptoms and NO limitation to strength, function, or range of motion which would interfere with flight duties.
- Severity mild to moderate
FAA criterion: the severity is mild to moderate.
[ ] Severity is mild to moderate.
- Co-morbid conditions and psoriatic arthritis
The worksheet's note: if co-morbid conditions are present, it points to the corresponding page, and if there is psoriatic arthritis, to the arthritis page.
NOTE: If co-morbid conditions are present, see corresponding page. If psoriatic arthritis, see arthritis page.
- The subtype of psoriasis
FAA criterion: the worksheet's causes include most subtypes, to include guttate psoriasis and plaque psoriasis. It names pustular psoriasis and erythrodermic psoriasis as not acceptable.
Causes [ ] Most subtypes to include: guttate psoriasis, plaque psoriasis. Not acceptable: pustular psoriasis, erythrodermic psoriasis.
- Medications from the worksheet's list
FAA criterion: topical medication(s) and/or azathioprine (Imuran) and/or methotrexate (Trexall) and/or any single medication from the worksheet's list below it, after a 2-week ground trial. The worksheet says the combinations acceptable for CACI include topical medication, methotrexate and any single agent listed, which it writes as "Topical medication + Methotrexate + Any single agent listed".
Medications for condition Combinations acceptable for CACI Include: • Topical medication + • Methotrexate + • Any single agent listed … [ ] Topical medication(s) and/or [ ] azathioprine (Imuran) and/or [ ] methotrexate (Trexall) and/or [ ] Any single medication listed below after a 2-week ground trial and:
- A single medication after a 2-week ground trial, and its post-dose observation time
The worksheet's list of single medications, each after a 2-week ground trial, by post-dose observation time. No post-dose observation time: apremilast (Otezla). A 4-hour post-dose observation time: adalimumab (Humira or FDA approved biosimilar), certolizumab (Cimzia), etanercept (Enbrel), guselkumab (Tremfya), ixekizumab (Taltz), risankizumab (Skyrizi), secukinumab (Cosentyx), ustekinumab (Stelara). A 24-hour post-dose observation time: infliximab (Inflect; Remicade; Renflexis). The worksheet notes that biologics do not have generic; they have biosimilar.
Any single medication listed below after a 2-week ground trial and: No post-dose observation time: apremilast (Otezla) - PD4E 4-hour post-dose observation time: adalimumab ( Humira or FDA approved biosimilar*) - TNF certolizumab (Cimzia) - TNF etanercept (Enbrel) - TNF guselkumab (Tremfya) - IL ixekizumab (Taltz) - IL risankizumab (Skyrizi) - IL secukinumab (Cosentyx) - IL ustekinumab (Stelara) - IL 24-hour post-dose observation time: infliximab (Inflect; Remicade; Renflexis) - TNF … *Biologics do not have generic; they have biosimilar.
If the examiner defersSpecial Issuance
The table's last row is All others, including erythrodermic psoriasis, pustular psoriasis and severe psoriasis, and the table marks it DEFER.
What the FAA lists to send
- Item 1. A current, detailed clinical progress note generated from a clinic visit with the treating dermatologist or rheumatologist no more than 90 days before the exam. The table says it must include a detailed summary of the history of the condition; current medications, dosage, and side effects (if any); physical exam findings; results of any testing performed; diagnosis; assessment and plan; prognosis; and follow-up.
- Item 2. The table says the clinical progress note must specifically include whether any co-morbid conditions are present, and documentation of counseling on guideline-directed screening for co-morbid conditions.
Show the FAA's words: if the examiner defers
When the examiner defers
- Reason 1
The table's last row is All others, including erythrodermic psoriasis, pustular psoriasis and severe psoriasis, and the table marks it DEFER.
All others including: • Erythrodermic psoriasis • Pustular psoriasis • Severe psoriasis … DEFER Submit the information to the FAA for a possible Special Issuance
What the FAA lists to send
- Item 1
A current, detailed clinical progress note generated from a clinic visit with the treating dermatologist or rheumatologist no more than 90 days before the exam. The table says it must include a detailed summary of the history of the condition; current medications, dosage, and side effects (if any); physical exam findings; results of any testing performed; diagnosis; assessment and plan; prognosis; and follow-up.
A current, detailed Clinical Progress Note generated from a clinic visit with the treating Dermatologist or Rheumatologist no more than 90 days prior to the AME exam. It must include: A detailed summary of the history of the condition; Current medications, dosage, and side effects (if any); Physical exam findings; Results of any testing performed; Diagnosis; Assessment and plan; Prognosis; and Follow-up.
- Item 2
The table says the clinical progress note must specifically include whether any co-morbid conditions are present, and documentation of counseling on guideline-directed screening for co-morbid conditions.
The Clinical Progress Note must specifically include: If any co-morbid conditions are present Documentation of counseling on guideline-directed screening for co-morbid conditions
After the FAA decides
AASIThe AASI sheet for psoriasis says an FAA physician makes the first decision and grants the Authorization. After that, the sheet says the examiner may reissue under the Authorization when the pilot provides what it lists.
Show the FAA's words: after the FAA decides
An FAA physician provides the initial certification decision and grants the Authorization in accordance with 14 CFR § 67.401. … AMEs may re-issue an airman medical certificate under the provisions of an Authorization, if the applicant provides the following:
What a Special Issuance is
The Guide says an Authorization for Special Issuance, valid for a specified period, may be granted at the Federal Air Surgeon's discretion to a person who does not meet the established medical standards, if the person shows to the satisfaction of the Federal Air Surgeon that the duties authorized by the class of certificate applied for can be performed without endangering public safety during the period the Authorization would be in force.
How the FAA pathways workAt later examsAASI
- First and second class
- Every year
- Third class
- At each required exam
The worksheet says first- and second-class applicants must provide this information every year, and third-class applicants must provide it with each required exam.
Show the FAA's words: how often the FAA asks again
Applicants for first- or second- class must provide this information annually; applicants for third-class must provide the information with each required exam.
Under an FAA Authorization, the AASI sheet for psoriasis lists what the pilot provides for the examiner to reissue. That is the Authorization itself, and a current, detailed clinical progress note from a clinic visit with the treating rheumatologist or dermatologist no more than 90 days before the exam, which must specifically describe if co-morbid conditions are present, they are appropriately managed, and that the pilot was counseled regarding guideline-directed screening for co-morbid conditions.
Show the FAA's words: at later exams
AMEs may re-issue an airman medical certificate under the provisions of an Authorization, if the applicant provides the following: … An Authorization granted by the FAA; and … A current, detailed Clinical Progress Note generated from a clinic visit with the treating Rheumatologist or Dermatologist no more than 90 days before the AME exam. … It must specifically describe if co-morbid conditions are present, they are appropriately managed, and that the individual was counseled regarding guideline-directed screening for co-morbid conditions.
What AASI is
AASI stands for AME Assisted Special Issuance. The Guide describes it as a process that lets the examiner reissue a certificate under the provisions of an Authorization for Special Issuance, to an applicant who has a medical condition that is disqualifying under 14 CFR part 67.
How the FAA pathways workThe Authorization granted by the FAA
The AASI sheet's list for a reissue begins with the Authorization the FAA granted.
Show the FAA's words: The Authorization granted by the FAA
AMEs may re-issue an airman medical certificate under the provisions of an Authorization, if the applicant provides the following: … An Authorization granted by the FAA; and
A progress note from the treating rheumatologist or dermatologist
For a reissue the AASI sheet asks for a current, detailed clinical progress note generated from a clinic visit with the treating rheumatologist or dermatologist, no more than 90 days before the exam.
Show the FAA's words: A progress note from the treating rheumatologist or dermatologist
A current, detailed Clinical Progress Note generated from a clinic visit with the treating Rheumatologist or Dermatologist no more than 90 days before the AME exam.
What the progress note must include
The AASI sheet says the note must include a detailed interim summary; current medications, dosage, and side effects (if any); physical exam findings; results of all testing performed; diagnosis; assessment and plan (prognosis); and follow-up. It says the note must specifically describe if co-morbid conditions are present, they are appropriately managed, and that the pilot was counseled regarding guideline-directed screening for co-morbid conditions.
Show the FAA's words: What the progress note must include
It must include: … A detailed interim summary; … Current medications, dosage, and side effects (if any); … Physical exam findings; … Results of all testing performed; … Diagnosis; … Assessment and plan (prognosis); and … Follow-up. … It must specifically describe if co-morbid conditions are present, they are appropriately managed, and that the individual was counseled regarding guideline-directed screening for co-morbid conditions.
What the Authorization letter comes with
The AASI sheet says the Authorization letter comes with attachments that specify the information the treating physicians must provide for the reissue determination.
Show the FAA's words: What the Authorization letter comes with
The Authorization letter is accompanied by attachments that specify the information that treating physician(s) must provide for the re-issuance determination.
When the examiner defers a reissue
The AASI sheet says the examiner must defer, and describe in Block 60 what item(s) caused the deferral, if the treating physician's evaluation or the examiner's exam identifies any other disqualifying medical conditions or therapy not previously reported; the development of symptoms or medication side effects incompatible with aviation safety; or that guideline directed screening for co-morbid conditions is not addressed.
Show the FAA's words: When the examiner defers a reissue
AME must defer and describe in Block 60 what item(s) caused the deferral if the treating physician evaluation or AME exam identifies any of the following: … Any other disqualifying medical conditions or therapy not previously reported; … Development of symptoms or medication side effects incompatible with aviation safety; or … Guideline directed screening for co-morbid conditions are not addressed.
Good to know
Points from the FAA's own documents that are easy to miss.
What a progress note must include
In most cases it should come from a visit with the treating physician no more than 90 days ago, and cover the history, medications with dosages and side effects, exam findings, test results, diagnosis, assessment and plan, prognosis and follow-up. The FAA's sheet says to make sure the physician adds the prognosis. A portal note or an After Visit Summary that does not meet these criteria is not enough, and neither is a simple "ok to fly" letter. The FAA's documents also call it a status report.
Show the FAA's words: good to know, 1
your patient portal to print out “notes” or an “After Visit Summary (AVS).” … Patient Portal notes or an AVS that do not meet the criteria listed below for a detailed Clinical Progress Note are NOT sufficient for FAA purposes. … To be “current,” in MOST CASES, the detailed Clinical Progress Note should be from an evaluation in which you saw your treating physician no more than 90 days ago. … It Must include the following items: … A summary of the history of the condition, … Current medications, dosages, and side effects (if any); … Clinical exam findings; … Results of any testing performed; … Diagnosis; … Assessment and Plan; … Prognosis (This item may not be on a standard progress note, make sure your physician adds this information.); and … Follow-up … Please note: A letter stating, “Mr. Smith is ok to fly” (or any other simple note), is NOT a current, detailed Clinical Progress Note and is NOT acceptable. … You may also see this called a “current status report” or “status report” in current FAA Guidance. Any reference to a “status report” equals the criteria listed on this sheet.
Skin-only disease on topical medication
Mild to moderate disease confined to the skin and treated with topical medication only is ISSUE where the examiner can determine it is under control, current medications are acceptable, and no symptoms would interfere with flight or safety related duties.
Show the FAA's words: good to know, 2
A. Mild to moderate disease confined to the skin AND Treated with topical medication only … If the AME can determine the condition is under control, current medications are acceptable, and no symptoms that would interfere with flight or safety related duties: ISSUE
Psoriatic arthritis goes to arthritis
Both the table and the worksheet send psoriatic arthritis to arthritis. The table points to the CACI arthritis worksheet, and the worksheet to the arthritis page.
Show the FAA's words: good to know, 3
If psoriatic arthritis present, see CACI – Arthritis Worksheet
If psoriatic arthritis, see arthritis page.
Three statements for Block 60
The worksheet says the examiner must note one of three in Block 60: CACI qualified psoriasis, with no documents sent to the FAA; current or previous SI/AASI but now CACI qualified; or NOT CACI qualified, deferred, with supporting documents submitted.
Show the FAA's words: good to know, 4
AME MUST NOTE in Block 60 one of the following: … CACI qualified Psoriasis. (Documents do not need to be submitted to the FAA.) … Has current OR previous SI/AASI but now CACI qualified Psoriasis. … NOT CACI qualified Psoriasis. I have deferred. (Submit supporting documents.)
The first AASI is deferred to the FAA
For a first-time AASI application for this condition, with all the medical information needed for a determination, the AASI sheet says the examiner must defer and submit all of it to the AMCD or RFS for the initial determination.
Show the FAA's words: good to know, 5
If this is first-time application for an AASI for the above disease/condition, and the applicant has all the requisite medical information necessary for a determination, the AME must defer and submit all of the documentation to the AMCD or RFS for the initial determination.
A second AASI sheet names psoriasis
The FAA also publishes an AASI for arthritis and/or psoriasis. It asks for the type of arthritis or psoriasis, a general assessment and its effect on daily activities, and the medications with comment on side effects, and has its own reasons to defer.
Show the FAA's words: good to know, 6
Special Issuances - Arthritis and/or Psoriasis … The type of arthritis or psoriasis; … A general assessment of condition and effect on daily activities; … The name and dosage of medication(s) used for treatment and/or prevention with comment regarding side effects; and … The Examiner must defer to the AMCD or Region if: … The applicant has developed any associated systemic manifestations; … For arthritis - new joints have become involved; … The applicant required change in medication used for control of the disease; or … The applicant is taking steroids doses equivalent to more than 20mg of prednisone per day ( steroid conversion calculator ).
FAA sources
Every FAA document this page relies on, with the FAA's own date and the date Crosscheck last read it. The documents to print open at the FAA, so they are always the FAA's current ones.
- Open to print: CACI – Psoriasis Worksheet, a PDF at the FAA, in a new tab
- Psoriasis Disposition TableOpen to print: Psoriasis Disposition Table, a PDF at the FAA, in a new tab
Examiner can issue, Special Issuance
- Open to print: AASI – Psoriasis, a PDF at the FAA, in a new tab
- Open at the FAA: AASI – Arthritis and/or Psoriasis, a page at the FAA, in a new tab
- Open at the FAA: Pilot Information – What a Detailed Clinical Progress Note must contain, a PDF at the FAA, in a new tab
This reports what the FAA has published. It is not medical advice, and it does not say how the FAA or an examiner will decide a case.